In conclusion, maternal melatonin therapy counterbalances the effects of high methyl-donor diet-induced programmed hypertension, primarily related to the reduction of oxidative stress, increased urinary NO2− level, and decreased expression of sodium transporters in the kidney. The gene discussed is SLC5A4; the disease is hypertensive disorder.